focus -WSS

focus

author：leisure time 2025-10-01 15:30:54 - browse：9796

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Roche's accidental data boosts hopes for anti

knowledge

WSS

How CRISPR works, explained in two minutes

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Vivek Ramaswamy made waves in the debate, much as in biotech

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Failure, not just success, should guide future doctors

DeSantis wants to import drugs. Biden’s FDA blasted his plan

focus

focus

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Failure, not just success, should guide future doctors

Duchenne breakthrough therapy leaves behind pioneering families

Intellia plays down concerns on accidental germline transmission

Sports medicine is finally prioritizing gender equality

How the drug

ChatGPT in medicine: STAT answers readers' burning questions

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

23andMe had bad news about my health. I wish a person had delivered it

Trans patients at the end of life deserve respect and dignity

focus

Failure, not just success, should guide future doctors

It was time to plan for my old age. If only I could stop crying

Vivek Ramaswamy made waves in the debate, much as in biotech

Roche's accidental data boosts hopes for anti

Failure, not just success, should guide future doctors

How CRISPR works, explained in two minutes

focus

knowledge

Wikipedia

leisure time